Submission of Intimation of Voting results and Scrutinizer''s Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories (formerly Macro International) held an Extra-Ordinary General Meeting on 6 November 2025 via video conferencing, where all three resolutions were passed with 100% approval and zero dissent. The resolutions covered: (1) increasing the company's authorized share capital and amending the Capital Clause of the MOA (ordinary), (2) acquiring 100% stake in Sriven Pharmachem India Private Limited through a share swap via preferential allotment (special), and (3) approving the related party transaction tied to this acquisition (ordinary). Of the 2,969 total shareholders on the cutoff date (30 October 2025), 64 voted, with 5,036,943 shares (46.77% of the 10,770,000 outstanding shares) participating — all in favour. Promoters holding 1,959,284 shares voted entirely in favour, and public non-institutional holders cast 3,077,659 votes, also 100% in favour. No institutional shareholders participated in the voting.
Shareholders have cleared the path for an acquisition of Sriven Pharmachem India funded entirely through a share swap, which means new equity will be issued to the target's owners — this will dilute existing shareholders once the swap ratio and new shares are disclosed. While the 100% approval and zero dissent suggest shareholder comfort, retail investors should watch for the forthcoming preferential allotment details (issue price, swap ratio, post-issue dilution) and the target company's financials before judging the deal's value.